UroGen Pharma (URGN) Tax Provisions (2019 - 2026)

UroGen Pharma (URGN) has 7 years of Tax Provisions data on file, last reported at -$4.8 million in Q1 2026.

• Quarterly Tax Provisions fell 1317.35% year-over-year to -$4.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.4 million (down 43.48% YoY) and the FY2025 annual result came in at -$35.3 million, down 23.68% from the prior year.
• Tax Provisions climbed to -$4.8 million in Q1 2026, from -$35.6 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $1.0 million in Q2 2025 to a low of -$35.6 million in Q4 2025.
• A 5-year average of -$6.8 million and a median of $32000.0 in 2022 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2025 — Tax Provisions surged 2571.05% — and 2026, when it plunged 1317.35%.
• Tracing URGN's Tax Provisions over 5 years: stood at -$25.9 million in 2022, then climbed by 12.47% to -$22.7 million in 2023, then slipped by 26.59% to -$28.7 million in 2024, then slipped by 24.12% to -$35.6 million in 2025, then soared by 86.61% to -$4.8 million in 2026.
• The last three Tax Provisions figures came in at -$4.8 million (Q1 2026), -$35.6 million (Q4 2025), and -$1.1 million (Q3 2025), per Business Quant data.